Reply: Dual-Integrin ?±v?23- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (68Ga-BBN-RGD)

摘要

>REPLY: I would like to respond to the wonderful commentary from Dr. Andrei Iagaru regarding a paper my colleagues and I recently published in The Journal of Nuclear Medicine (id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1). The heterodimer comprises two monomers that target two distinct types of receptors and are covalently linked. Consequently, one major advantage of the heterodimer over the corresponding monomers is the multivalency effect, resulting in improved binding affinity and an increased number of effective receptors (id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2). However, after covalent conjugation, the heterodimer is a new compound, which would show different in vivo pharmacokinetics from the monomers. Thus, it is not surprising that bombesin-arginine-glycine-aspartate (RGD) showed different distribution patterns within normal organs and tissues from either RGD or bombesin alone. If we mix RGD and bombesin, the similarity of the background would be improved, but that is not the purpose of this study.